Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 118

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 118
---
58,139,277 58,432,796 57,846,173 57,581,382 

See accompanying Notes to Condensed Consolidated Financial Statements.

2

Table of Contents    

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Comprehensive (Loss) Income

(Unaudited)

Three Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Net (loss) income$(103,433)$947,915 $(304,742)$770,248 Other comprehensive incomeUnrealized gain on available-for-sale securities1,396 4,465 3,569 3,861 Comprehensive (loss) income$(102,037)$952,380 $(301,173)$774,109 

See accompanying Notes to Condensed Consolidated Financial Statements.

3

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Stockholders' Equity

(Unaudited)Common StockAdditionalPaid-InCapitalAccumulatedOtherComprehensive Income(Loss)AccumulatedDeficitTreasury StockTotalStockholders’Equity(in thousands, except share amounts)SharesAmountSharesAmountBalance at December 31, 202473,372,696 $73 $2,493,811 $(1,518)$(148,924)(16,216,411)$(802,486)$1,540,956 Unrealized gain on available-for-sale securities— — — 1,883 — — — 1,883 Common stock issued under stock incentive plan and ESPP730,496 1 1,618 — — — — 1,619 Stock-based compensation expense— — 11,359 — — — — 11,359 Net loss— — — — (89,289)— — (89,289)Balance at March 31, 202574,103,192 $74 $2,506,788 $365 $(238,213)(16,216,411)$(802,486)$1,466,528 Unrealized gain on available-for-sale securities— — — 290 — — — 290 Common stock issued under stock incentive plan and ESPP151,764 — 65 — — — — 65 Stock-based